Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Second-line rituximab–bendamustine versus rituximab–gemcitabine–oxaliplatin in diffuse large B-cell lymphoma in the real world
PaperCitations, authors & open-access status
Second-line rituximab–bendamustine versus rituximab–gemcitabine–oxaliplatin in diffuse large B-cell lymphoma in the real world is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 13 citations, 2019 year and hybrid oa status.
13
Citations
2019
Year
hybrid
OA Status